 LOS ANGELES--BUSINESS WIRE--Second Sight Medical Products, Inc. NASDAQ: EYES the Company or Second Sight, a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health NIH of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis the Orion Trial, grant UH3NS103442. 